Skip to main content
SpringerLink
Log in

Issues and Concerns in the Management of Systemic Candidiasis

  • Chapter
  • First Online:
Current Trends and Concerns in Infectious Diseases

Part of the book series: Emerging Infectious Diseases of the 21st Century ((EIDC))

  • 727 Accesses

Abstract

Invasive candidiasis is the most common systemic fungal infection in hospitalized patients in the developed world, associated with a mortality of up to ≥40% even in patients treated with antifungals. It is a major cause of healthcare-associated or nosocomial infection induced by several Candida species; the most common species being Candida albicans, but the prevalence of the different species varies with geographical location and type of hospital practice. In some centers and countries there has been a shift in the frequency of non-C. albicans invasive disease with increased resistance to azoles such as fluconazole, the antifungal drug of choice in many countries and healthcare centers. Also there are increased reports of resistance to the newer class of antifungals, the echinocandins, which has replaced fluconazole as first choice in many guidelines and centers. Of major concern is the emergence of the novel multidrug resistant yeast, Candida auris, in the last 10 years that has been spreading globally with inter- and intra-hospital transmission. This chapter discusses the evidence to support guidelines recommendations for an echinocandin as initial therapy for invasive candidiasis over fluconazole.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bongomin F, Gago S, Oladele RO, Denning DW (2017) Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi (Basel) 3:57

    Article  Google Scholar 

  2. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM, Lockhart SR, Park BJ (2015) Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from the population-based surveillance. PLoS One 10:e120452. https://doi.org/10.1371/journal.pone.0120452.

    Article  Google Scholar 

  3. McCarty TP, Pappas PG (2016) Invasive candidiasis. J Infect Dis Clin North Am 30:103–124

    Article  Google Scholar 

  4. Perlroth J, Choi B, Spellberg B (2007) Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 45:321–346

    Article  PubMed  Google Scholar 

  5. Vincent JL, Rello J, Marshall J et al (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329

    Article  CAS  PubMed  Google Scholar 

  6. Kulberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 373:1445–1456

    Article  CAS  Google Scholar 

  7. Koh AY, Kohler JR, Coggshall KT, Van Rooijen N, Pier GB (2008) Mucosal damage and neutrophils are required for Candida albicans dissemination. PLoS Pathog 4:e35. https://doi.org/10.1371/journal.ppat.0040035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gazendam RP, van der Geer A, Roos D, van der Berg TK, Kuijpers TW (2016) How neutrophils kill fungi. Immunol Rev 273:299–311

    Article  CAS  PubMed  Google Scholar 

  9. Duhring S, Germerodt S, Skerka C, Zipfel PF, Dandekar T, Schuster S (2015) Host-pathogen interaction between the human innate immune system and Candida albicans—understanding and modeling defense and evasion strategies. Front Microbiol. https://doi.org/10.3389/fmicb.2015.00625

  10. Nash EE, Peters BM, Fidel PL, Noverr MC (2015) Morphology-independent virulence of Candida species during polymicrobial intra-abdominal infections with Staphylococcus aureus. Infect Immun 84:90–98

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Delano MJ, Ward PA (2016) Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 126:23–31

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chin VK, Lee TV, Rusliza B, Chong PP (2016) Dissecting Candida albicans infection from the perspective of C. albicans virulence and omics approaches on host-pathogen interaction: a review. Int J Mol Sci 17:1643

    Article  PubMed Central  CAS  Google Scholar 

  13. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ (2018) Invasive candidiasis. Nat Rev/Dis Primers 4:8026. https://doi.org/10.1038/nrdp.2018.26

    Article  Google Scholar 

  14. Plantinga TS, Johnson MD, Scott WK et al (2012) Toll-like receptor polymorphisms increase susceptibility to candidemia. J Infect Dis 205:934–943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kumar V, Cheng S-C, Johnson MD et al (2014) Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidemia. Nat Commun 5:4675

    Article  CAS  PubMed  Google Scholar 

  16. Johnson MD, Plantinga TS, van de Vosse E et al (2012) Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis 54:502–510

    Article  CAS  PubMed  Google Scholar 

  17. Yapar N (2014) Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 10:95–105

    Article  PubMed  PubMed Central  Google Scholar 

  18. Richardson M, Lassa-Florl C (2008) Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 14(Suppl 4):5–24

    Article  PubMed  Google Scholar 

  19. Arendrup MC (2014) Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 20(Suppl 6):42–48

    Article  CAS  PubMed  Google Scholar 

  20. Arendrup M, HJorn T, Frimodt-Moller N (2002) In vivo pathogenicity of eight medically relevant Candida species. Infection 30:286–291

    Article  CAS  PubMed  Google Scholar 

  21. Welsh RM, Sexton DJ, Forsberg K, Vallabhaneni S, Litvintseva A (2019) Insights into the unique nature of the East Asian clade of the emerging pathogenic yeast Candida auris. J Clin Microbiol 57:e00007–e00019. https://doi.org/10.1128/JCM.00007-19

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, Ang HC (2011) First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 49:3139–3142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kwon YJ, Shin JH, Byeon SA et al (2019) Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol 57:e01624–e01618. https://doi.org/10.1128/JCM.01624-18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S (2018) Approach to the investigation and management of patients with Candida auris, an emerging multi-resistant yeast. Clin Infect Dis 66:306–311

    Article  PubMed  Google Scholar 

  25. Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, Vallbhaneni S (2019) Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol 57:1–12

    Article  PubMed  Google Scholar 

  26. Cadnum JL, Shaikh AA, Piedrahita CT et al (2018) Relative resistance of the emerging fungal pathogen Candida auris and other Candida species to killing by ultraviolet light. Infect Control Hosp Epidemiol 39:94–96

    Article  PubMed  Google Scholar 

  27. Mayer F, Wilson D, Hube B (2013) Candida albicans pathogenicity mechanisms. Virulence 4:119–128

    Article  PubMed  PubMed Central  Google Scholar 

  28. Fakhim H, Vaezi A, Damaoui E et al (2018) Comparative virulence of Candida auris with Candida haelomuloni, Candida glabrata and Candida albicans in a murine model. Mycoses 61:377–382

    Article  PubMed  Google Scholar 

  29. Rebolledo M, Sarria JC (2013) Intra-abdominal fungal infections. Curr Opin Infect Dis 26:441–446

    PubMed  Google Scholar 

  30. Hall AM, Poole LA, Renton B, Fisher M, Neal T, Halloran CM, Cox T, Hampshire PA (2013) Prediction of invasive candidiasis in critically ill patients with severe acute pancreatitis. Crit Care 17:R49. https://doi.org/10.1186/cc12569

    Article  PubMed  PubMed Central  Google Scholar 

  31. Montavers P, Dupont H, Gauzit R et al (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34:646–652

    Article  Google Scholar 

  32. Bassetti M, Righti E, Montravers P, Cornely OA (2018) What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother 73(Suppl 1):i14–i25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnosis will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284–1292

    Article  PubMed  Google Scholar 

  34. Vergidis P, Clancy CJ, Shields RK, Park SY, Wildfeuer BN, Simmons RL, Nguyen MH (2016) Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS One 11:e0153247. https://doi.org/10.1371/journal.pone.0153247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bassetti M, Righi E, Ansaldi F et al (2015) A multicenter study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41:1601–1610

    Article  PubMed  Google Scholar 

  36. Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, Alexander BDF (2011) Quantitation of Candida CFU in the initial positive blood cultures. J Clin Microbiol 49:2879–2883

    Article  PubMed  PubMed Central  Google Scholar 

  37. Montravers P, Dupont H, Eggimann P (2013) Intra-abdominal candidiasis: the guidelines—forgotten non-candidemic invasive candidiasis. Intensive Care Med 39:2226–2230

    Article  PubMed  Google Scholar 

  38. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts J-M (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31:752–757

    Article  PubMed  Google Scholar 

  39. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance of candida isolation from peritoneum in surgical patients. Lancet 334:1437–1440

    Article  Google Scholar 

  40. Clancy CJ, Nguyen MH (2018) Diagnosing invasive candidiasis. J Clin Microbiol 56:e01909–e01917

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L et al (2015) T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 60:892–899

    Article  CAS  PubMed  Google Scholar 

  42. Clancy CJ, Pappas PG, Vazquez J et al (2018) Detecting infections rapidly and easily for candidemia trial, part 2 [DIRECT2]: a prospective, multicenter study of the T2Candida Panel. Clin Infect Dis 66:1678–1686

    Article  CAS  PubMed  Google Scholar 

  43. Leon C, Ruiz-Santana S, Saaverdra P et al (2016) Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care 20:149

    Article  PubMed  PubMed Central  Google Scholar 

  44. Munoz P, Vena A, Machado M et al (2018) T2MR contributes to the very early diagnosis of complicated candidemia. A prospective study. J Antimicrob Chemother 73(Suppl 4):iv13–iv19

    Article  CAS  PubMed  Google Scholar 

  45. CLSI (2012) Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth international supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne

    Google Scholar 

  46. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP (2014) Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol 52:994–997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M (2013) Echinocandins and triazole antifungal susceptibility profiles for clinical yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51:2571–2581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lee I, Zaoutis TE, Fishman NO, Morales KH, Nachamkin I, Lautenback E (2010) Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance. Am J Infect Control 38:456–460

    Article  CAS  PubMed  Google Scholar 

  50. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD (2017) Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. https://doi.org/10.3389/fmicb.2016.02173

  51. Alexander BD, Johnson MD, Pfieffer CD et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732

    Article  PubMed  PubMed Central  Google Scholar 

  52. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW (2014) FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819–825

    Article  CAS  PubMed  Google Scholar 

  53. Shields RK, Nguyen MH, press EG, Updike CL, Clancy CJ (2013) Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528–3535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Vallabhaneni S, Cleveland AA, Farley MM et al (2015) Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014. Open Forum Infect Dis 2:ofv163. https://doi.org/10.1093/0fid/ofv163

    Article  PubMed  PubMed Central  Google Scholar 

  55. Tan TY, Hsu LY, Alejandria MM et al (2016) Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol 54:471–477

    Article  CAS  PubMed  Google Scholar 

  56. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN (2019) Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis 6(Suppl 1):S79–S94

    Article  PubMed  PubMed Central  Google Scholar 

  57. Chowdhury A, Prakash A, Sharma C et al (2018) A multicenter study of antifungal susceptibility patterns among 350 Candida auris isolates [2009-17] in India: role of ERG11 and FKS genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891–899

    Article  CAS  Google Scholar 

  58. Romera D, Aguilera-Corrrea JJ, Gadea I, Vinuela-Sandoval L, Garcia-Rodriguez J, Esteban J (2019) Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs. J Med Microbiol. https://doi.org/10.1099/jmm.0.001036

    Article  CAS  PubMed  Google Scholar 

  59. Pappas PG, Kauffmann CA, Andes DR et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:409–417

    Article  PubMed  Google Scholar 

  60. Eschenauer GA, Nguyen M-H, Clancy CJ (2015) Is fluconazole or an echinocandin the agent of choice for candidemia. Ann Pharmacother 49:1068–1074

    Article  CAS  PubMed  Google Scholar 

  61. Sobel JD, Revankar SG (2007) Echinocandins: first-choice or first-line therapy for invasive candidiasis? N Engl J Med 356:2525–2526

    Article  CAS  PubMed  Google Scholar 

  62. Rex JH, Bennett JE, Sugar AM et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325–1330

    Article  CAS  PubMed  Google Scholar 

  63. Reboli AC, Rotstein C, Pappas PG et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472–2482

    Article  CAS  PubMed  Google Scholar 

  64. Andes DR, Safdar N, Badley JW et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54:1110–1122

    Article  CAS  PubMed  Google Scholar 

  65. Puig-Asensio M, Peman J, Zaragoza R et al (2014) Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 42:1423–1432

    Article  CAS  PubMed  Google Scholar 

  66. Bailey S, Leroy O, Azoulay E et al (2017) Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: a post-hoc casual inference model using the AmarCAND2 study. J Infect 74:408–417

    Article  Google Scholar 

  67. Lopez-Cortez LE, Almirante B, Cuenca-Estrella M et al (2016) Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect:733.e1–8

    Google Scholar 

  68. Murri R, Scoppettuolo G, Ventura G et al (2016) Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis 35:187–193

    Article  CAS  PubMed  Google Scholar 

  69. Timsit JF, Azoulay E, Schwebel C et al (2016) Empiric micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA 316:1555–1564

    Article  CAS  PubMed  Google Scholar 

  70. Knitsch W, Vincent JL, Utzolino S et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61:1671–1678

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Ostrosky-Zeichner L, Shoham S, Vasquez J et al (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk critical care setting. Clin Infect Dis 58:1219–1226

    Article  CAS  PubMed  Google Scholar 

  72. Jensen RH, Johansen HK, Soes LM et al (2015) Post-treatment antifungal resistance among colonizing Candida isolates in candidemic patients: results from a systematic multicenter study. Antimicrob Agents Chemother 60:1500–1508

    Article  CAS  PubMed  Google Scholar 

  73. Reboli AC, Shor AF, Rotstein C et al (2011) Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis 11:261

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Puig-Asensio M, Fernandez-Ruiz M, Aguado JM et al (2016) Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections. Antimicrob Agents Chemother 60:3291–3300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Fernandez-Ruiz M, Guinea J, Lora-Pablos D et al (2017) Impact of fluconazole susceptibility on the outcome of patients with candidemia: data from a population-based surveillance. Clin Microbiol Infect 23:672

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

    I. W. Fong

Authors
  1. I. W. Fong
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fong, I.W. (2020). Issues and Concerns in the Management of Systemic Candidiasis. In: Current Trends and Concerns in Infectious Diseases. Emerging Infectious Diseases of the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-030-36966-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36966-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36965-1

  • Online ISBN: 978-3-030-36966-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation